Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA FR0010609263), leader in the optical biopsy market and maker of Cellvizio, the fastest way to see cancer, today announced that physicians around the world will soon have access to a new Optical Biopsy platform through the launch of EVA, the Endomicroscopy Virtual Assistant, dedicated to provide a seamless Cellvizio experience from image acquisition to review and documentation in the patient’s health record. EVA is powered by the new Cellvizio software, today available for sale in Europe and in the USA for digestive, pulmonary and urological applications*.
Help employers find you! Check out all the jobs and post your resume.
